💬In plain words
What the trial is, and whether it could suit you
The aim of the study is to
1. To determine whether treatment with Erythropoiesis-stimulating agents (in the form of Aranesp®) affects platelet function, and how.
2. To determine whether salicylate treatment changes the effect of EPO (erythropoietin) on platelet function.
Sign in to get the eligibility rules as simple questions to take to your doctor.
📋 Eligibility rules (as published)
Inclusion Criteria:
* Chronic hemodialysis, peritoneal dialysis or CKD 5 treated conservatively
* aged 18-85
* indication for treatment with Erythropoiesis-stimulating agents (ESA)
Exclusion Criteria:
1. Known allergy to ASA
2. Known contraindication to ASA, e.g. recent bleeding episode.
3. Known indication for ASA. If the patient is being treated with ASA, and the physician does not find any indication for this treatment, this can be stopped, and the patient included after 4 weeks.
4. Raised reticulocyte count
5. Current anticoagulant therapy, e.g. warfarin, ADP receptor inhibitor (excepting short-term anticoagulant therapy in connection with dialysis)
6. Short expected length of life
7. Inability to give informed consent
8. Expected non-compliance
9. Active cancer - except for non-melanoma skin-cancer
10. Iron deficiency (defined as a reticulocyte Hgb \<1,8 fmol. Patients can be included when their iron deficiency has been cured. .
11. Change in ESA dosis \>33,3% within previous 2 month
12. Fertile women. Pregnancy is excessively rare in dialysis patients. Women who are \<50 years, or who are still menstruating will be excluded from the study.
13. Stable Aranesp ® dose \<20 µg/week.
Medicinsk afdeling, SUH Roskilde
Roskilde, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
HealthTeky